William Phd Link Sells 12,500 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Director William Phd Link sold 12,500 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $62.12, for a total transaction of $776,500.00. Following the completion of the transaction, the director owned 106,786 shares of the company’s stock, valued at $6,633,546.32. This trade represents a 10.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tarsus Pharmaceuticals Stock Up 2.9%

Tarsus Pharmaceuticals stock traded up $1.75 during midday trading on Wednesday, hitting $62.55. 462,278 shares of the stock were exchanged, compared to its average volume of 606,366. Tarsus Pharmaceuticals, Inc. has a 1 year low of $38.51 and a 1 year high of $85.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.74 and a quick ratio of 3.71. The firm has a market cap of $2.69 billion, a P/E ratio of -54.87 and a beta of 0.49. The company has a 50 day moving average price of $63.62 and a two-hundred day moving average price of $69.67.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.24. The company had revenue of $162.05 million during the quarter, compared to analysts’ expectations of $149.60 million. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.19%. On average, sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -0.59 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Tuesday, April 21st. Wall Street Zen raised Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. HC Wainwright reissued a “buy” rating and set a $88.00 price target on shares of Tarsus Pharmaceuticals in a research report on Monday, May 4th. Zacks Research lowered shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Finally, Lifesci Capital raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 16th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $90.67.

Institutional Trading of Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Tarsus Pharmaceuticals by 5.6% during the 4th quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company’s stock worth $196,476,000 after buying an additional 127,470 shares during the last quarter. TimesSquare Capital Management LLC increased its holdings in shares of Tarsus Pharmaceuticals by 24.3% in the 4th quarter. TimesSquare Capital Management LLC now owns 332,446 shares of the company’s stock valued at $27,221,000 after acquiring an additional 64,941 shares during the last quarter. Citigroup Inc. raised its position in shares of Tarsus Pharmaceuticals by 78.1% during the 3rd quarter. Citigroup Inc. now owns 40,591 shares of the company’s stock valued at $2,412,000 after acquiring an additional 17,797 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH raised its position in shares of Tarsus Pharmaceuticals by 19.9% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 109,857 shares of the company’s stock valued at $8,995,000 after acquiring an additional 18,267 shares in the last quarter. Finally, D.A. Davidson & CO. bought a new position in Tarsus Pharmaceuticals during the fourth quarter worth $1,493,000. 90.01% of the stock is owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.